The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials

摘要: Background and Purpose Although bevacizumab (BV) has been approved as second-line therapy for recurrent glioblastoma (GB), the efficacy safety of BV patients with newly diagnosed GB remain unclear. Methodology/Principal Findings We systematically searched electronic databases (PubMed, EMBASE, OVID, etc.) to identify related studies published from January 1966 August 2016. Eight randomized controlled trials including a total 2,185 were included. We found that median progression-free survival (PFS) was higher in group than standard (ST) (pooled hazard ratio, 0.73; 95%CI, 0.62–0.86; P = 0.0001). Compared ST, improved PFS rate at 6 months (OR 3.33, 95% CI 2.73–4.06, p<0.00001) 12 2.10, 1.74–2.54, p<0.00001). There no significant differences overall between ST groups (OR, 1.01; 0.83–1.23; 0.95). The had rates 1.41; CI, 1.09–1.84; 0.01) 1.23; 1.02–1.48; 0.03), but low 36-month follow-up 0.57; 0.32–0.98; 0.04). For incidence adverse events, three outcomes be significantly different groups, hypertension (8.37% vs. 1.62%, p<0.000001), proteinuria (7.65% 0%, p<0.001), fatigue (14.54% 9.01%, p 0.05). Conclusions/Significance Our study indicates combination did not improve result longer PFS, maintaining quality life functional status. However, long-term use is associated events mortality. Study Registration This research registered PROSPERO. (Registration Number: CRD42016038247).